Results 41 to 50 of about 59,932 (250)

Remdesivir Inhibits Tubulointerstitial Fibrosis in Obstructed Kidneys

Frontiers in Pharmacology, 2021
Aim: Kidney impairment is observed in patients with COVID-19. The effect of anti-COVID-19 agent remdesivir on kidneys is currently unknown. We aimed to determine the effect of remdesivir on renal fibrosis and its downstream mechanisms.Methods: Remdesivir
Lin Xu, Lin Xu, Lin Xu, Lin Xu, Bo Tan, Di Huang, Di Huang, Di Huang, Di Huang, Meijie Yuan, Meijie Yuan, Tingting Li, Tingting Li, Ming Wu, Ming Wu, Ming Wu, Ming Wu, Chaoyang Ye, Chaoyang Ye, Chaoyang Ye, Chaoyang Ye   +20 more
doaj   +1 more source

Role of OATP4C1 in Renal Handling of Remdesivir and its Nucleoside Analog GS-441524: The First Approved Drug for Patients with COVID-19

Journal of Pharmacy & Pharmaceutical Sciences, 2021
Purpose. Remdesivir and its active metabolite are predominantly eliminated via renal route; however, information regarding renal uptake transporters is limited.
Toshihiro Sato, Masamitsu Maekawa, Nariyasu Mano, Takaaki Abe, Hiroaki Yamaguchi   +4 more
doaj   +1 more source

Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics

Frontiers in Immunology, 2022
The SARS-CoV-2 virus needs multiple copies for its multiplication using an enzyme RNA-dependent RNA polymerase (RdRp). Remdesivir inhibits viral RdRp, controls the multiplication of the virus, and protects patients.
Bhaswati Chatterjee, Suman S. Thakur
doaj   +1 more source

The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and meta-analysis

Therapeutic Advances in Drug Safety, 2021
Introduction: Remdesivir, an experimental antiviral drug has shown to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), both in vitro and in vivo .
Chenchula Santenna, Kota Vidyasagar, Krishna Chaitanya Amarneni, Sai Nikhila Ghanta, Balakrishnan Sadasivam, Saman Pathan, R. Padmavathi   +6 more
doaj   +1 more source

Co-Administration of Remdesivir and Azithromycin May Protect against Intensive Care Unit Admission in COVID-19 Pneumonia Requiring Hospitalization: A Real-Life Observational Study

Antibiotics, 2022
The benefits of remdesivir treatment, with or without co-administration of antibiotics such as azithromycin, are uncertain in COVID-19 pneumonia. The aim of this retrospective single-center study was to assess the effects of remdesivir, with or without ...
Andrea Ticinesi, Domenico Tuttolomondo, Antonio Nouvenne, Alberto Parise, Nicoletta Cerundolo, Beatrice Prati, Ilaria Zanichelli, Angela Guerra, Nicola Gaibazzi, Tiziana Meschi   +9 more
doaj   +1 more source

Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort study.

PLoS ONE, 2021
ObjectivesRemdesivir is one of the most widely recommended and used medications for COVID-19 treatment. However, different outcomes have been reported for hospitalized patients with COVID-19 treated with remdesivir. Specifically, the effect of the timing
Hawra Ali Hussain Alsayed, Fatemeh Saheb Sharif-Askari, Narjes Saheb Sharif-Askari, Ali Al Sayed Hussain, Qutayba Hamid, Rabih Halwani   +5 more
doaj   +2 more sources

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

New England Journal of Medicine, 2021
Background Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in symptomatic, nonhospitalized patients with Covid-19 who are at high risk for disease ...
R. Gottlieb, C. E. Vaca, R. Paredes, J. Mera, B. Webb, Gilberto Pérez, Godson Oguchi, P. Ryan, B. Nielsen, M. Brown, Ausberto Hidalgo, Yessica Sachdeva, S. Mittal, O. Osiyemi, J. Skarbinski, K. Juneja, R. Hyland, A. Osinusi, Shuguang Chen, G. Camus, Mazin Abdelghany, Santosh Davies, Nicole Behenna-Renton, F. Duff, F. Marty, Morgan J. Katz, A. Ginde, Sam Brown, Joshua T. Schiffer, Joshua A. Hill   +29 more
semanticscholar   +1 more source

Remdesivir Strongly Binds to RNA-Dependent RNA Polymerase, Membrane Protein, and Main Protease of SARS-CoV-2: Indication From Molecular Modeling and Simulations

Frontiers in Pharmacology, 2021
Development of new drugs is a time-taking and expensive process. Comprehensive efforts are being made globally toward the search of therapeutics against SARS-CoV-2.
Faez Iqbal Khan, Tongzhou Kang, Haider Ali, Dakun Lai   +3 more
doaj   +1 more source

Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trials

Frontiers in Pharmacology, 2022
Since December 2019, COVID-19 has spread across the world almost through 2.5 years. As of 16 June 2022, the cumulative number of confirmed cases of COVID-19 worldwide has reached 542.62 million, and the death toll has risen to 6.33 million.
Zhenchao Wu, Zhenchao Wu, Zhifei Han, Zhifei Han, Beibei Liu, Beibei Liu, Ning Shen, Ning Shen   +7 more
doaj   +1 more source

The utility of remdesivir in SARS-CoV-2: A single tertiary care center experience from a developing country

Exploratory Research in Clinical and Social Pharmacy, 2022
Background: Remdesivir is a monophosphoramidate prodrug of an adenosine analog, and it has a broad-spectrum antiviral activity against paramyxoviruses, flaviviruses, and coronaviruses.
Muhammad Irfan Malik, Sardar Al Fareed Zafar, Muna Malik, Fabiha Qayyum, Iqra Akram, Ammarah Arshad, Khalid Waheed, Jodat Saleem, Abdul Jabbar, Muhammad Junaid Tahir, Zohaib Yousaf   +10 more
doaj   +1 more source